Dinesh Chandra

The aim of present study,  To formulate and characterized  proniosome contain flurbiprofen in a gel formulation for the treatment of rheumatoid arthritis and enhanced skin targeted effect, sustained & prolonged drug release, enhanced skin bioavailability by using different type of non ionic surfactant & cholesterol. The batches were designed using Box Behnken Design and prepared by coacervation phase separation method. Optimized formulation (PNGopt) showed drug entrapment efficiency of 74.46% and particle size 215nm. In-vitro drug release from PNGopt was found to be 84.15 in 24 hrs. The In-vitro drug release was best explained by zero order kinetics as the plot showed highest linearity and release was governed by Quasi Fickian diffusion.

Tablet is the most popular dosage form of all existing dosage forms , but in some cases due to the large size of dosage forms, in case of uncooperative, pediatric and dysphasia patients, it may create  problems, to overcome this , a new form of dosage form is developed, which is known as fast dissolving tablets or mouth dissolving tablets. These dosage forms are also used to attain instant higher concentration of drug in body for immediate actions. Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Fenugreek seed powder was added to this formuation because of  its various pharmacological benefits as well as its self disintegrating property. Mouth dissolving tablets were prepared using direct compression method .Formulations were optimized to develop tablets having minimum possible disintegration time. Tablets were evaluated for hardness, weight variation, friability, wetting time, disintegration time and stability. The main objective of the present research is formulation and evaluation  of mouth dissolving tablets of gliclazide which is an antidiabetic drug ,containing fenugreek seed powder as disintegrating agent.

The present investigation has been undertaken with aim to formulation and evaluation of etoricoxib gel with different gelling agent and different penetration enhancer. Etoricoxib is highly selective cyclooxygenase-2 (COX-2) inhibitor. In this present study gel with carbopol, HPMC and Na-CMC as gelling agent prepared with different penetration enhancer like propyl glycol, oleic acid. Menthol oil. Formulation were evaluated for pH, stability study, spreadibilty, extrudabilty, bioadhesive (ex-vivo), skin irritation, viscosity, appearance and In-vitro drug diffusion. The formulation of Etoricoxib topical gel was prepared using carbopol, HPMC and Na-cmc in three batches A, B and C. With the consideration of all formulation characteristic and parameter we selected batch-A formulation for further study of anti-inflammatory and anti-analgesic activity. It was concluded that the Etoricoxib gel formulation containing carbopol with increase concentration of propyl glycol 10% and 2% oleic acid (OA) was suitable for topical application and it shows comparable result with market product and shows much better result of formulation, anti-inflammatory and anti-analgesic activity.

The aim of this study was to prepare Diclofenac potassium (DP) microspheres by using Double Emulsion-solvent evaporation method with ethyl cellulose (EC) and Eudragit polymers. An attempt was made to formulate a sustained release dosage form of diclofenac potassium, to minimize frequent dosing as well as reducing or eliminating local side effects by avoiding the drug release in the upper gastro-intestinal tract Poly vinyl alcohol containing 2% (w/w) span 80 was the external phase and polymer -drug solution was the internal phase. EC and Eudragit were used to encapsulate diclofenac potassium. By using different formulation variables, six different formulations (F1, F2, F3, F4, F5, & F6) were prepared. The resulting microspheres obtained, were more spherical in shape and showed more entrapment efficiency. The size of the microspheres varied between 346-695 μm and as high as 96.24% loading efficiency for Eudragit and 82.34% for EC was obtained. In vitro release study was carried out in 0.1 N hydrochloric acid solution (pH 1.2) for first 2 hours followed by in phosphate buffer solution (pH 6.8) for next 4 hours. After first 2 hours of dissolution in 0.1 N hydrochloric acid, EC microspheres released 23% of drug and Eudragit released 7% of drug. The formulations were found to be effective in providing controlled release of drug for a longer period of time.

The colon drug delivery system has gained recent importance in delivery of the drug to the colon. These system facilitate the delivery of the drug to the colon and mainly releases the drug in the colonic environment and thereby reduces various side effects of conventional dosage forms like lower dose is required and hence lowering the side effects caused by higher doses. In the present study natural polysaccharide approach is employed and sesbania gum powder was used as a carrier for delivery of the drug to the colon . Satranidazole was selected as a drug of choice because it is most potent nitroimidazole derivative and clinically useful against common protozoa, it is twice as effective as other nitroimidazoles against amoebiasis. Colon targeted tablet of satranidazole can maintain minimum inhibitory concentration for desired duration in fewer doses with fewer side effects. The aim of the present research work is to develop core tablets of satranidazole and compression coated with different ratios of sesbania gum powder. All the formulations were then subjected for evaluation and were tested for hardness, drug content uniformity an in vitro drug release studies. The compression coated formulation CCS 2 released less than 5% of satranidazole drug in the physiological environment of stomach and intestine, when the dissolution studies was further continued in simulated colonic fluids the compression coated tablets with 150mg of sesbania gum powder released another 70% of satranidazole in the colon after degradation by colonic bacteria at the end of 12 hrs.

The proniosomal approach helps to solve the problem regarding stability and provides higher entrapment efficiency over conventional system. Proniosomal gel is a liquid crystalline- compact niosomal hybrid which is prepared by dissolving surfactant in small amount of suitable solvent and least amount of aqueous phase. This compact gel can be converted to niosomes hydration. Proniosomes can entrap hydrophilic as well as lipophillic drugs. Proniosomal gel offers a versatile vesicle drug delivery concept with potential for drug delivery via transdermal rout. Over the last few years an inclusive research has been done over pro-vesicular approach for transdermal drug delivery. Skin has a very tough diffusion barrier inhibiting penetration of drug moiety which is rate limiting barrier for penetration of drugs. There are several approaches that deal with penetration enhancement across the skin. Vesicular and provesicular systems are promising amongst them. Vesicular systems including (niosomes, ethosomes, transfersomes and liposomes) are promising systems to cross this permeation barrier.

Over the last few years an inclusive research has been done over provesicular approach for transdermal drug delivery. Skin has a very tough diffusion barrier inhibiting penetration of drug moiety which is rate limiting barrier for penetration of drugs. There are several approaches that deal with penetration enhancement across the skin. Vesicular and provesicular systems are promising amongst them. Vesicular systems including (niosomes, ethosomes, transfersomes and liposomes) are promising systems to cross this permeation barrier. The proniosomal approach helps to solve the problem regarding stability and provides higher entrapment efficiency over conventional system. Proniosomal gel is a liquid crystalline- compact niosomal hybrid which is prepared by dissolving surfactant in small amount of suitable solvent and least amount of aqueous phase. This compact gel can be converted to niosomes hydration. Proniosomes can entrap hydrophilic as well as lipophillic drugs. Proniosomal gel offers a versatile vesicle drug delivery concept with potential for drug delivery via transdermal rout.

By name, colonic drug delivery refers to targeted delivery of drugs into the lower GI tract, which occurs primarily in the large intestine (i.e. colon).Targeted drug delivery to the colon would therefore ensure direct treatment at the disease site, lower dosing and fewer systemic side effects. In addition to the local therapy, the colon also can be utilised as a portal for the drugs into the systemic circulation. Colon targeted drug delivery has gained recent importance for the treatment of colonic diseases and systemic delivery of therapeutic proteins and peptides. Treatment could be more effective if it is possible for drug to be directly delivered to colon. This article gives a detailed information related to colon, various approaches current and novel which are employed for delivery of drugs to the colon and advantages and limitation of colonic drug delivery over conventional drug delivery along with evaluation.